Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PLD3 | Q8IV08 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507760 | 0.88 | TSHR (0.46) | EPHX2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL6498258 | 0.88 | TSHR (0.46) | EPHX2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL6506039 | 0.81 | MAPT (0.36) | EPHX2ALDH1A1TSHRDPP4 | |
| SCHEMBL6500205 | 0.80 | DPP9 (0.46) | ALDH1A1DPP4 | |
| SCHEMBL6510576 | 0.79 | DPP4 (0.52) | ALDH1A1MEN1KMT2ADPP4GAA | |
| SCHEMBL6428780 | 0.77 | ALDH1A1 (0.38) | ALDH1A1NPC1TSHRMEN1KMT2A | |
| SCHEMBL6500702 | 0.76 | TSHR (0.30) | TSHR | |
| SCHEMBL6427850 | 0.75 | TSHR (0.40) | EPHX2ALDH1A1NPC1TSHRMEN1 | |
| SCHEMBL6387572 | 0.74 | ATM (0.35) | ALDH1A1NPC1MEN1KMT2ARAB9A | |
| SCHEMBL6428790 | 0.73 | HPGD (0.39) | ALDH1A1NPC1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | EPHX2 641/4885ALDH1A1 67/4885NPC1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.